

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – March 9, 2011 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. January 12, 2011 DUR Minutes – Vote
 - B. January 13, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for November 2010
 - B. Retrospective Drug Utilization Review Response for October 2010
 - C. Medication Coverage Activity Audit for January 2011, February 2011
 - D. Pharmacy Help Desk Activity Audit for January 2011, February 2011

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Benign Prostate Hyperplasia (BPH) Medications – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Tribenzor[®], Tekamlo[®], Nexiclon XR[®], and Catapres-TTS[®] – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Robinson, Dr. Muchmore, Chairman

7. **Action Item – Vote to Prior Authorize Silenor[™] – See Appendix E.**
 - A. Current Authorization Criteria for Hypnotics Category
 - B. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Vote to Prior Authorize Kapvay[®] and Xyrem[®] – See Appendix F.**
A. COP Recommendations

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Osteoporosis Medications and 30 Day Notice to Prior Authorize Prolia[™] and Atelvia[™] – See Appendix G.**
A. Current Authorization Criteria
B. Utilization Review
C. Prior Authorizations Review
D. Market News and Updates
E. COP Recommendations
F. Utilization Details
G. New Product Details
H. FDA Drug Safety Communication

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

10. **Drug Utilization Review of Topical Steroids – See Appendix H.**
A. Overview
B. Utilization Review
C. Market News and Updates
D. COP Recommendations
E. Utilization Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Lamisil[®] Granules – See Appendix I.**
A. Current Authorization Criteria
B. Utilization Review
C. Prior Authorizations Review
D. COP Recommendations
E. Utilization Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix J.**
13. **Future Business**
A. Utilization Review of Diabetes Products
B. Annual Review of Plavix[®] and Effient[®]
C. Annual Review of Triptans
D. Annual Review of Fibromyalgia Products
E. New Product Reviews
14. **Adjournment**